HEALTHJul 17 · 13:02 UTCSTAT NEWSEd Silverman

STAT+: Pharmalittle: We’re reading about rising drug shortages, GSK coughing up a trial loss, and more

The U.S. experienced 227 active medication shortages in Q2 2026, with 48% being sole-source products and 10% involving life-saving contrast agents. GSK abandoned development of camlipixant, a chronic cough drug acquired for $2 billion, after Phase 3 trials showed limited efficacy.

Nexus surfaces and summarizes. The full story lives at the source.

Mentioned

American Society of Health-System PharmacistsorganizationGSKorganizationBellus HealthorganizationcamlipixanttopicP2X3 antagonisttopicPhase 3 trialstopiccontrolled substancestopiccontrast agentstopic

Spot something wrong with this article?Report a problem →

Forward this

Related Signal

Adjacent reporting

HEALTHJun 9 · 20:46 UTC
STAT+: The shortage of many medicines in the U.S. remains a ‘systemic’ problem, a new analysis finds
HEALTHMay 1 · 11:39 UTC
Medication shortage chaos: The vital drugs missing from Britain's pharmacy shelves - and experts warn the issue is about to get WORSE
HEALTHMay 11 · 13:12 UTC
STAT+: Pharmalittle: We’re reading about Medicare and Alzheimer’s drugs, estrogen patch shortages, and more
HEALTHJun 4 · 13:17 UTC
STAT+: Pharmalittle: We’re reading about fewer pharma investments in Germany, growing U.S. layoffs, and more